Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4943990 | 0.83 | CYP3A4 (0.33) | CYP3A4 | |
| SCHEMBL4945225 | 0.76 | KMT2A (0.50) | ALDH1A1KMT2ATDP1ATMTP53 | |
| SCHEMBL4944614 | 0.74 | KDM4E (0.34) | ALDH1A1KMT2ATP53TSHRRAB9A | |
| SCHEMBL1544511 | 0.73 | TLR8 (0.40) | ALDH1A1KMT2AATMTP53TSHR | |
| SCHEMBL1544197 | 0.72 | KCNH2 (0.40) | ALDH1A1KMT2AATMTP53CYP3A4 | |
| SCHEMBL4946212 | 0.71 | ALDH1A1 (0.42) | ALDH1A1KMT2ATSHRCYP3A4RAB9A | |
| SCHEMBL4946188 | 0.69 | KMT2A (0.33) | ALDH1A1KMT2ATDP1ATMTP53 | |
| SCHEMBL4294154 | 0.64 | KMT2A (0.49) | ALDH1A1KMT2ATDP1ATMTP53 | |
| SCHEMBL4943994 | 0.64 | CYP3A4 (0.49) | ALDH1A1KMT2ATDP1ATMTSHR | |
| SCHEMBL4946170 | 0.64 | MEN1 (0.36) | ALDH1A1KMT2ARAB9ASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080045571-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045571-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | GRM5, GRIK5, GRM2 | ALDH1A1 3875/4885KMT2A 2030/4885TDP1 3525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.